Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder

CNS Neuroscience and Therapeutics

Volumn 18, Issue 6, 2012, Pages 441-451

  Soskin, David P ^a   Carl, Jenna R ^b   Alpert, Jonathan ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Combined cognitive behavioral and pharmacological treatment; Dopamine and the reward system; Emotional temperament; Major depressive disorder

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DEXAMPHETAMINE; MODAFINIL; PAROXETINE; PLACEBO; REBOXETINE; VENLAFAXINE;

AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; BEHAVIOR; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; EMOTION; FACIAL EXPRESSION; HIGH RISK POPULATION; HUMAN; MAJOR DEPRESSION; MOTIVATION; NERVE POTENTIAL; NEUROSCIENCE; PREFRONTAL CORTEX; REVIEW; REWARD; SINGLE DRUG DOSE; SYMPTOM; TASK PERFORMANCE; TEMPERAMENT; TREATMENT DURATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EMOTIONS; FEMALE; HUMANS; MALE; TEMPERAMENT;

EID: 84861892845     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00318.x     Document Type: Review

References (92)

1. Rosenhan DL. On being sane in insane places. Science 1973;179:250-258.
2. Kendell RE, Cooper JE, Gourlay AJ, Copeland JR, Sharpe L, Gurland BJ. Diagnostic criteria of American and British psychiatrists. Arch Gen Psychiatry 1971;25:123-130.
3. Wilson M. DSM-III and the transformation of American psychiatry: A history. Am J Psychiatry 1993;150:399-410.
4. Brown TA, Barlow DH. A proposal for a dimensional classification system based on the shared features of the DSM-IV anxiety and mood disorders: Implications for assessment and treatment. Psychol Assess 2009;21:256-271.
5. Wilamowska ZA, Thompson-Hollands J, Fairholme CP, Ellard KK, Farchione TJ, Barlow DH. Conceptual background, development, and preliminary data from the unified protocol for transdiagnostic treatment of emotional disorders. Depress Anxiety 2010;27:882-890.
6. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG. Remission and relapse in major depression: A two-year prospective follow-up study. Psychol Med 1995;25:1161-1170.
7. American Psychiatric Association. Practice guideline for the treatment of patients with major depression. 2nd ed. American Psychiatric Association, Washington, 2000.
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006;163:1905-1917.
9. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
10. Shorter E, Tyrer P. Separation of anxiety and depressive disorders: Blind alley in psychopharmacology and classification of disease. BMJ 2003;327:158-160.
11. Katz MH. Multivariable analysis. Cambridge University Press, New York, 1999.
12. Watson D, Tellegen A. Toward a consensual structure of mood. Psychol Bull 1985;98:219-235.
13. Watson D. Mood and temperament. Guilford Press, New York, 2000.
14. Fava M, Anderson K, Rosenbaum JF "Anger attacks": Possible variants of panic and major depressive disorders. Am J Psychiatry 1990;147:867-870.
15. Fava M, Hwang I, Rush AJ, Sampson N, Walters EE, Kessler RC. The importance of irritability as a symptom of major depressive disorder: Results from the National Comorbidity Survey Replication. Mol Psychiatry 2010;15:856-867.
16. Watson D, Weber K, Assenheimer JS, Clark LA, Strauss ME, McCormick RA. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. J Abnorm Psychol 1995;104:3-14.
17. Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA. Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. J Abnorm Psychol 1995;104:15-25.
18. Nierenberg AA, Eidelman P, Wu Y, Joseph M. Depression: An update for the clinician. Focus 2005;3:3-12.
19. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton depression rating scale: Has the gold standard become a lead weight? Am J Psychiatry 2004;161:2163-2177.
20. Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorders. Annu Rev Psychol 1998;49:377-412.
21. Brown TA, Chorpita BF, Barlow DH. Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal. J Abnorm Psychol 1998;107:179-192.
22. Brown TA. Temporal course and structural relationships among dimensions of temperament and DSM-IV anxiety and mood disorder constructs. J Abnorm Psychol 2007;116:313-328.
23. Clark LA. Temperament as a unifying basis for personality and psychopathology. J Abnorm Psychol 2005;114:505-521.
24. Rasmussen N. America's first amphetamine epidemic 1929-1971: A quantitative and qualitative retrospective with implications for the present. Am J Public Health 2008;98:974-985.
25. Fanous A, Gardner CO, Prescott CA, Cancro R, Kendler KS. Neuroticism, major depression and gender: A population-based twin study. Psychol Med 2002;32:719-728.
26. Hettema JM, Prescott CA, Kendler KS. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am J Psychiatry 2004;161:1581-1587.
27. Gotlib IH, Hamilton JP, Cooney RE, Singh MK, Henry ML, Joormann J. Neural processing of reward and loss in girls at risk for major depression. Arch Gen Psychiatry 2010;67:380-387.
28. McCabe C, Cowen PJ, Harmer CJ. Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl) 2009;205:667-677.
29. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-337.
30. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry 2010;167:748-751.
31. Brown TA, Barlow DH. A proposal for a dimensional classification system based on the shared features of the DSM-IV anxiety and mood disorders: Implications for assessment and treatment. Psychol Assess 2009;21:256-271.
32. Agency for Health Care Policy and Research. Clinical practice guideline: Depression in primary care: treatment of major depression. U.S. Department of Health and Human Services, Rockville, 1993.
33. Gelenberg AJ, Thase ME, Meyer RE, et al. The history and current state of antidepressant clinical trial design: A call to action for proof-of-concept studies. J Clin Psychiatry 2008;69:1513-1528.
34. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 1988;54:1063-1070.
35. Carver CL, White TL. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scales. J Person Soc Psychol 1994;67:319-333.
36. Costa PT, Jr., McCrae RR. Revised NEO personality inventory (NEO-PI-R) and NEO five-factor inventory (NEO-FFI) professional manual. Psychological Assessment Resources, Odessa, 1992.
37. Naragon-Gainey K, Watson D, Markon KE. Differential relations of depression and social anxiety symptoms to the facets of extraversion/positive emotionality. J Abnorm Psychol 2009;118:299-310.
38. Sloan D, Kring A. Measuring changes in emotion during psychotherapy: Conceptual and methodological issues. Clin Psychol: Sci Prac 2007;14:307-322.
39. Bagby RM, Levitan RD, Kennedy SH, Levitt AJ, Joffe RT. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: Evidence of non-specificity. Psychiatry Res 1999;86:211-216.
40. Du L, Bakish D, Ravindran AV, Hrdina PD. Does fluoxetine influence major depression by modifying five-factor personality traits? J Affect Disord 2002;71:235-241.
41. Gracious KS. Do SSRIs affect personality traits. Br J Psychiatry 1999;175:287.
42. Marchevsky D. Selective serotonin reuptake inhibitors and personality change. Br J Psychiatry 1999;175:589-590.
43. Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Schalet B. Personality change during depression treatment: A placebo-controlled trial. Arch Gen Psychiatry 2009;66:1322-1330.
44. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62:409-416.
45. Quilty LC, Meusel LA, Bagby RM. Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. J Affect Disord 2008;111:67-73.
46. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 2009;166:1178-1184.
47. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009;194:535-540.
48. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006;59:816-820.
49. Chandra P, Hafizi S, Massey-Chase RM, Goodwin GM, Cowen PJ, Harmer CJ. NK1 receptor antagonism and emotional processing in healthy volunteers. J Psychopharmacol 2010;24:481-487.
50. Danish University Antidepressant Group. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 2009;195:102-108.
51. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990;18:289-299.
52. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138.
53. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
54. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006;60:1350-1355.
55. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008;42:134-140.
56. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993;21:30-34.
57. Stahl SM, Felker A. Monoamine oxidase inhibitors: A modern guide to an unrequited class of antidepressants. CNS Spectr 2008;13:855-870.
58. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373-379.
59. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: A prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004;61:877-889.
60. Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ. Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol 2009;12:169-179.
61. Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 1998;46:547-554.
62. Di Matteo V, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 2001;22:229-232.
63. Kumar P, Waiter G, Ahearn T, Milders M, Reid I, Steele JD. Abnormal temporal difference reward-learning signals in major depression. Brain 2008;131:2084-2093.
64. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145.
65. Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53(Suppl):52-56.
66. Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990;10:343-345.
67. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002;5:147-151.
68. Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. Br J Psychiatry 2009;195:211-217.
69. McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 2010;67:439-445.
70. Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. Br J Psychiatry 2009;195:211-217.
71. Taneja I, Haman K, Shelton RC, Robertson D. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol 2007;27:76-79.
72. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001;49:81-96.
73. Blood AJ, Zatorre RJ. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proc Natl Acad Sci U S A 2001;98:11818-11823.
74. Kunig G, Leenders KL, Martin-Solch C, Missimer J, Magyar S, Schultz W. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport 2000;11:3681-3687.
75. Martin-Solch C, Magyar S, Kunig G, Missimer J, Schultz W, Leenders KL. Changes in brain activation associated with reward processing in smokers and nonsmokers. A positron emission tomography study. Exp Brain Res 2001;139:278-286.
76. Haber SN, Knutson B. The reward circuit: Linking primate anatomy and human imaging. Neuropsychopharmacology 2010;35:4-26.
77. Andrews W, Parker G, Barrett E. The SSRI antidepressants: exploring their "other" possible properties. J Affect Disord 1998;49:141-144.
78. Bagby RM, Levitan RD, Kennedy SH, Levitt AJ, Joffe RT. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: Evidence of non-specificity. Psychiatry Res 1999;86:211-216.
79. Tomarken AJ, Dichter GS, Freid C, Addington S, Shelton RC. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord 2004;78:235-241.
80. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006;16:391-402.
81. Diener E, Iran-Nejad A. The relationship in experience between various types of affect. J Person Soc Psychol 1986;50:1031-1038.
82. Watson D. The vicissitudes of mood measurement: effects of varying descriptors, time frames, and response formats on measures of positive and negative affect. J Pers Soc Psychol 1988;55:128-141.
83. Dichter GS, Tomarken AJ, Freid CM, Addington S, Shelton RC. Do venlafaxine XR and paroxetine equally influence negative and positive affect? J Affect Disord 2005;85:333-339.
84. Nelson JC, Portera L, Leon AC. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry 2005;57:1535-1542.
85. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002;159:1702-1710.
86. Harmon-Jones E, Allen JJ. Behavioral activation sensitivity and resting frontal EEG asymmetry: Covariation of putative indicators related to risk for mood disorders. J Abnorm Psychol 1997;106:159-163.
87. Sutton SK, Davidson RJ. Prefrontal brain asymmetry: A biological substrate of the behavioral approach and the behavioral inhibition systems. Psychol Sci 1997;8:204-210.
88. Gotlib IH, Ranganath Cl, Rosenfeld JP. Frontal EEG alpha asymmetry, depression, and cognitive functioning: Neuropsychological perspectives on affective and anxiety disorders. Cogn Emot 1998;12:449-478.
89. Henriques JB, Davidson RJ. Left frontal hypoactivation in depression. J Abnorm Psychol 1991;100:535-545.
90. Henriques JB, Glowacki JM, Davidson RJ. Reward fails to alter response bias in depression. J Abnorm Psychol 1994;103:460-466.
91. Depue RA, Iacono WG. Neurobehavioral aspects of affective disorders. Annu Rev Psychol 1989;40:457-492.
92. Depue RA, Collins PF. Neurobiology of the structure of personality: Dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci 1999;22:491-517.